Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer
- PMID: 27458169
- PMCID: PMC5303001
- DOI: 10.18632/oncotarget.10767
Epigenetics in myeloid derived suppressor cells: a sheathed sword towards cancer
Abstract
Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of cells composed of progenitors and precursors to myeloid cells, are deemed to participate in the development of tumor-favoring immunosuppressive microenvironment. Thus, the regulatory strategies targeting MDSCs' expansion, differentiation, accumulation and function could possibly be effective "weapons" in anti-tumor immunotherapies. Epigenetic mechanisms, which involve DNA modification, covalent histone modification and RNA interference, result in the heritable down-regulation or silencing of gene expression without a change in DNA sequences. Epigenetic modification of MDSC's functional plasticity leads to the remodeling of its characteristics, therefore reframing the microenvironment towards countering tumor growth and metastasis. This review summarized the pertinent findings on the DNA methylation, covalent histone modification, microRNAs and small interfering RNAs targeting MDSC in cancer genesis, progression and metastasis. The potentials as well as possible obstacles in translating into anti-cancer therapeutics were also discussed.
Keywords: DNA methylation; epigenetics; microRNA (miRNA); myeloid derived suppressor cell (MDSC); small interfering RNA (siRNA).
Conflict of interest statement
The authors declare no potential conflict of interests.
Figures

Similar articles
-
Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer.Clin Epigenetics. 2020 Jan 15;12(1):13. doi: 10.1186/s13148-020-0808-9. Clin Epigenetics. 2020. PMID: 31941522 Free PMC article.
-
Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.Curr Top Med Chem. 2017;17(16):1843-1857. doi: 10.2174/1568026617666161122121412. Curr Top Med Chem. 2017. PMID: 27875974 Review.
-
Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.Cancer Immunol Immunother. 2017 Aug;66(8):989-996. doi: 10.1007/s00262-017-1963-5. Epub 2017 Feb 21. Cancer Immunol Immunother. 2017. PMID: 28224211 Free PMC article. Review.
-
Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.Mol Immunol. 2015 Feb;63(2):579-85. doi: 10.1016/j.molimm.2014.08.002. Epub 2014 Aug 23. Mol Immunol. 2015. PMID: 25155994 Free PMC article.
-
IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer.Oncogene. 2017 May 25;36(21):2969-2980. doi: 10.1038/onc.2016.448. Epub 2017 Jan 16. Oncogene. 2017. PMID: 28092673
Cited by
-
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma.J Clin Invest. 2018 Dec 3;128(12):5505-5516. doi: 10.1172/JCI98060. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30260323 Free PMC article.
-
Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone.EMBO Rep. 2020 Jun 4;21(6):e50162. doi: 10.15252/embr.202050162. Epub 2020 Apr 21. EMBO Rep. 2020. PMID: 32314873 Free PMC article.
-
Connections between Metabolism and Epigenetic Modification in MDSCs.Int J Mol Sci. 2020 Oct 5;21(19):7356. doi: 10.3390/ijms21197356. Int J Mol Sci. 2020. PMID: 33027968 Free PMC article. Review.
-
Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.Oncotarget. 2017 Mar 21;8(12):19534-19546. doi: 10.18632/oncotarget.14663. Oncotarget. 2017. PMID: 28099946 Free PMC article.
-
Myeloid-derived suppressor cells (MDSC): When good intentions go awry.Cell Immunol. 2021 Apr;362:104302. doi: 10.1016/j.cellimm.2021.104302. Epub 2021 Feb 4. Cell Immunol. 2021. PMID: 33592540 Free PMC article. Review.
References
-
- Carroll J. New immunotherapies for cancer yield exciting results but high cost. Managed care. 2013;22:54–56. - PubMed
-
- Ileana E, Champiat S, Soria JC. Immune-checkpoints: the new anti-cancer immunotherapies [Article in French] Bulletin du cancer. 2013;100:601–610. - PubMed
-
- Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728–5739. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources